<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03025945</url>
  </required_header>
  <id_info>
    <org_study_id>CME and nepafenac 0.3%</org_study_id>
    <nct_id>NCT03025945</nct_id>
  </id_info>
  <brief_title>Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo</brief_title>
  <official_title>Pseudophakic Cystoid Macular Edema Prevention and Risk Factors; Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intuor Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intuor Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, double-masked, placebo-controlled clinical study to define the
      effective use of a topical non-steroidal anti-inflammatory drug added to topical steroid use
      after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular
      edema.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative clinical findings of cystoid macular edema</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1497</enrollment>
  <condition>Cystoid Macular Edema</condition>
  <arm_group>
    <arm_group_label>nepafenac 0.3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nepafenac 0.3% ophthalmic solution dosed once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sterile saline drops with a pH approximately of 7.0 and osmolality of 290 mOsm/kg, dosed at once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepafenac 0.3%</intervention_name>
    <arm_group_label>nepafenac 0.3%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <arm_group_label>Saline Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects, 18 and older subjects with visually significant cataracts and were to
             undergo phacoemulsification with implantation of an intracapsular positioned
             intraocular lens.

        Exclusion Criteria:

          -  previous uveitis (&lt;1 year) previous anterior segment intraocular surgery
             hypersensitivity or allergy to NSAIDs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean McCafferty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arizona Eye Consultants</affiliation>
  </overall_official>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2017</study_first_submitted>
  <study_first_submitted_qc>January 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2017</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Nepafenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

